TGFB1 and neoplasm: Using a complementary approach, several works have increased killing activity of tumoricidal populations, by activating the phagocytic capacity of DCs with stimulating agents such as capsaicin [66] or anti-TGF-β antibodies [104], and/or using DC-based vaccines, based on tumor antigen-loaded CD103+ DCs or on CD1+ DCs combined with the immune-adjuvant poly I:C (polyinosinic:polycytidylic acid) [105].